GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Halberd Corp (OTCPK:HALB) » Definitions » Total Current Assets

Halberd (Halberd) Total Current Assets : $0.01 Mil (As of Jul. 2023)


View and export this data going back to 2009. Start your Free Trial

What is Halberd Total Current Assets?

Total current assets includes Cash, Cash Equivalents, Marketable Securities, Total Receivables, Total Inventories, and Other Current Assets. Halberd's total current assets for the quarter that ended in Jul. 2023 was $0.01 Mil.

Halberd Total Current Assets Historical Data

The historical data trend for Halberd's Total Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Halberd Total Current Assets Chart

Halberd Annual Data
Trend Jul08 Jul22 Jul23
Total Current Assets
- 0.01 0.01

Halberd Semi-Annual Data
Jul08 Jul22 Jul23
Total Current Assets - 0.01 0.01

Halberd Total Current Assets Calculation

Total Current Assets are the asset that can be converted to cash or used to pay current liabilities within 12 months.

Halberd's Total Current Assets for the fiscal year that ended in Jul. 2023 is calculated as

Total Current Assets=Cash, Cash Equivalents, Marketable Securities+Total Receivables+Total Inventories+Other Current Assets
=0.007+0+0+0.002
=0.01

Halberd's Total Current Assets for the quarter that ended in Jul. 2023 is calculated as

Total Current Assets=Cash, Cash Equivalents, Marketable Securities+Total Receivables+Total Inventories+Other Current Assets
=0.007+0+0+0.002
=0.01

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Total Current Assets is linked to the Current Ratio, which is the result of dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations.

Total Current Assets is also linked to Working Capital, Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

Halberd  (OTCPK:HALB) Total Current Assets Explanation

In Ben Graham's calculation of liquidation value, inventory is only considered worth half of its book value, and accounts receivable is considered worth 75% of its value. Therefore the liquidation value is lower than calculated from total current assets.

Halberd's Liquidation Value for the quarter that ended in Jul. 2023 is

Liquidation value
= Cash, Cash Equivalents, Marketable Securities-Total Liabilities+(0.75 * Accounts Receivable)+(0.5 * Total Inventories)
=0.007-0.939+0.75 * 0+0.5 * 0
=-0.93

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Halberd Total Current Assets Related Terms

Thank you for viewing the detailed overview of Halberd's Total Current Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Halberd (Halberd) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Halberd Corp (OTCPK:HALB) » Definitions » Total Current Assets
Comparable Companies
TSSI SWMM SFHI VSR ETOLF ESOA ENG LYOPF BBHDF RCMT LMB CUUHF GV IBIBF LAYN EMFGF LOUIF ORN WLDN GLDD
Traded in Other Exchanges
N/A
Address
P.O. Box 25, Jackson Center, PA, USA, 16133
Website
https://www.halberdcorporation.com
Halberd Corp is a research-based biotechnology company seeking to discover and develop medical treatments for a range of diseases. The Company's extracorporeal treatment is designed to treat hard-to-cure blood-borne, neurologic and infectious diseases. The Company's patented methodology removes the appropriate bodily fluid from the patient, in a continuous fashion, like dialysis, or in a batch process, like blood sample testing.
Executives
John Christopher Maddox director, 10 percent owner, officer: President, COO, Treasurer and, other: Interim CFO 10755 VERNON, HUNTINGTON WOODS MI 48070
Mark Sven Lundquist director, 10 percent owner, officer: CEO, Secretary and Director 24655 TUDOR LANE, FRANKLIN MI 48025
Cocco Nicholas A. Jr. director 50104 N. JIMMY COURT, CHESTERFIELD MI 48047-1898
Leland Michael Thomas director 280 LASALLE PLACE, GROSSE POINTE FARMS MI 88236